PharmTech Drug Digest 11.20
News|Articles|January 13, 2022

In the Lab eNewsletter

  • Pharmaceutical Technology's In the Lab eNewsletter, February 2022
  • Volume 17
  • Issue 2

Fujifilm Grows Lab Space at North Carolina Facility

Fujifilm Diosynth Biotechnologies' 89,000 square-foot expansion of its BioProcess Innovation Center in Research Triangle Park, N.C., will double its capacity to support process characterization.

Fujifilm Diosynth Biotechnologies is expanding its BioProcess Innovation Center in Research Triangle Park (RTP), N.C., the company announced in a Jan. 5, 2022 press release.

The project, which will feature an additional 89,000 ft2 of laboratory space equipped with state-of-the-art analytical instrumentation, high throughput bioprocessing equipment, and automation technologies, is expected to double the company’s capacity to support process characterization programs and complements the enhanced capabilities at its UK facility. This expansion will also allow Fujifilm Diosynth Biotechnologies to further support its partners in guiding clinical process development that can create more robust commercial processes.

The expanded space is expected to be operational by mid-2024, which is also when approximately 145 new jobs are anticipated to open up, many of those positions being for researchers and scientists.

“ … We are delighted to be adding this additional capacity to support our growing pipeline of customers,” notes Christine Vannais, chief operating officer, Fujifilm Diosynth Biotechnologies, RTP, North Carolina, in a company press release. “The cutting-edge laboratory equipment and automation tools, combined with the deep technical expertise of our scientific community, will allow us to better serve our partners to rapidly generate and assess data to understand complex molecules, along with the processes used in their manufacture.”

Source: Fujifilm Diosynth Biotechnologies


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.